CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Idarucizumab (Drug Plan Submission)

Last Updated: May 17, 2016
Result type: Reports
Project Number: SR0492-000
Product Line: Reimbursement Review

Generic Name: Idarucizumab (Drug Plan Submission)

Brand Name: Praxbind

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Therapeutic Area: Reversal of dabigatran anticoagulant effects

Indications: Reversal of dabigatran anticoagulant effects

Submission Type: Initial

Project Status: Withdrawn